



Animal Models For Nephrotoxicity And Kidney Injury: A Comprehensive Review

AUTHAOR -: Ms. Sushma S. Aher, Dr. Mahendra A. Giri

Abstract

Nephrotoxicity and kidney injury remain major clinical challenges worldwide, contributing significantly to morbidity and mortality. Experimental animal models are indispensable tools for understanding renal pathophysiology and evaluating the safety of drugs. This review summarizes various animal models used to study nephrotoxicity, including drug-induced, chemical-induced, ischemia-reperfusion, surgical, and disease-based models. Mechanisms of injury, biomarkers, evaluation methods, limitations, and recent advancements are also discussed. Despite limitations in translation, animal models continue to play a critical role in nephrology research and drug development.

Keywords-: Nephrotoxicity, Animal model, Kidney injury, Renal Toxicity, Experimental model

Introduction

Nephrotoxicity refers to the functional or structural damage of the kidneys caused by drugs, chemicals, toxins, or environmental agents^[1]. The kidneys are highly susceptible to toxic injury because they receive a large proportion of cardiac output (about 20–25%) and are actively involved in filtration, reabsorption, and secretion of substances^[2].

The basic functional unit of the kidney is the nephron, which includes the glomerulus and renal tubules. Many nephrotoxic agents primarily affect the proximal tubules, as these cells are metabolically active and involved in active transport^[3].

Classification of Kidney Injury

Kidney injury is broadly classified into:

2.1 Acute Kidney Injury (AKI)

- Rapid decline in renal function
- Characterized by increased serum creatinine and reduced urine output^[5].

2.2 Chronic Kidney Disease (CKD)

- Progressive and irreversible loss of kidney function
- Often associated with diabetes and hypertension^[6].

2.3 Types Based on Pathology

- Glomerular injury
- Tubular injury
- Interstitial injury
- Vascular injury

Importance of Animal Models

1. Understanding Pathophysiology

Animal models help in studying the **basic mechanisms of kidney injury**, including how damage occurs at cellular and molecular levels such as Oxidative stress and Inflammation. This improves our knowledge of disease progression^[14].

2. Preclinical Drug Safety Evaluation

Before human trials, drugs are tested in animals to identify nephrotoxic effects. For example, drugs like Cisplatin and Gentamicin are studied to understand their toxic impact on kidneys^[7].

3. Drug Development and Screening

Animal models are essential for:

- Screening new drug molecules
- Determining safe dosage
- Evaluating therapeutic efficacy

They help in identifying nephroprotective agents^[15].

4. Simulation of Human Diseases

Animal models can mimic human conditions like:

- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Diabetic nephropathy

This allows researchers to study disease behavior under controlled conditions^[5,6].

5. Study of Mechanisms of Toxicity

These models help identify:

- Cellular targets of toxins
- Mechanisms like apoptosis, necrosis, and mitochondrial dysfunction
- Role of reactive oxygen species (ROS) ^[16]

6. Biomarker Identification

Animal studies aid in discovering early biomarkers such as:

- KIM-1
- NGAL

These markers help in early detection of kidney injury^[16]

7. Testing Therapeutic Interventions

New treatments, drugs, or protective agents can be tested in animal models before clinical use, ensuring efficacy and safety^[18].

8. Controlled Experimental Environment

Animal models allow:

- Controlled dose administration
- Uniform experimental conditions
- Reproducible results^[3].

9. Understanding Disease Progression

Researchers can observe:

- Early-stage injury
- Progression to chronic disease
- Long-term effects of toxins^[2].

10. Evaluation of Histopathological Changes

Animal models help in studying structural kidney changes like:

- Tubular necrosis
- Glomerular damage
- Fibrosis^[12].

11. Cost-Effective and Time Efficient

Compared to human studies, animal experiments are:

- Faster
- Less expensive
- Easier to manage^[3].

12. Support for Regulatory Approval

Data from animal studies are required by regulatory authorities before approving new drugs for human use^[19].

4. Common Experimental Animals

- **Rats:** Most commonly used
- **Mice:** Preferred for genetic studies
- **Rabbits and Dogs:** Used in advanced studies
- **Emerging species:** Zebrafish, pigs

5. Types of Animal Models for Nephrotoxicity

Drug-Induced Models-These models mimic clinical drug-induced kidney injury.

Common agents:

- Cisplatin
- Gentamicin
- NSAIDs
- Vancomycin ^[7,8]

Mechanism:

- Tubular toxicity
- Oxidative stress
- Inflammation ^[9]

Drug-induced nephrotoxicity is a major cause of AKI in hospitalized patients.

Chemical-Induced Models- Chemicals are used to induce renal damage

- Mercuric chloride
- Carbon tetrachloride
- Ethylene glycol

These models simulate environmental toxin exposure and heavy metal toxicity^[10].

5.3 Ischemia-Reperfusion Injury (IRI) Models

- Temporary interruption of renal blood flow followed by reperfusion ^[11]
- Causes severe oxidative stress and inflammation

This model closely mimics clinical conditions like transplantation and shock.

5.4 Surgical Models

- **5/6 nephrectomy:** Mimics CKD ^[12]
- **Unilateral ureteral obstruction (UUO):** Causes fibrosis

Used to study long-term renal damage and progression.

5.5 Disease-Induced Models

- **Diabetic nephropathy:** Induced by streptozotocin
- **Hypertension models**
- **Sepsis-induced AKI** ^[13]

These models replicate systemic disease-associated kidney injury.

Animal models are widely used in nephrology research because they:

- Mimic human kidney diseases
- Help in understanding pathophysiological mechanisms

- Allow testing of drug safety and efficacy before clinical trials

These models play a crucial role in **preclinical evaluation of nephrotoxic drugs** and development of protective therapies.

Animal models for nephrotoxicity are widely used to study the mechanisms of kidney injury and to evaluate the safety of drugs and chemicals. These models are classified based on the method used to induce renal damage, such as drug-induced, chemical-induced, ischemia–reperfusion, surgical, and disease-induced models. Each model represents specific pathological mechanisms observed in human kidney diseases.

Drug-induced nephrotoxicity models are the most commonly used experimental systems because they closely resemble clinical conditions. Drugs such as Cisplatin, Gentamicin, and Vancomycin are frequently used to induce kidney injury in animals. The mechanism involves accumulation of these drugs in the proximal tubular cells, where they generate reactive oxygen species (ROS), leading to oxidative stress. This results in mitochondrial dysfunction, decreased ATP production, and activation of inflammatory pathways. Ultimately, these changes cause tubular necrosis and apoptosis, along with a reduction in glomerular filtration rate^[7,8,9].

Chemical-induced models use toxic substances such as Mercuric chloride and Carbon tetrachloride to produce renal damage. These chemicals exert their effects by binding to sulfhydryl groups of proteins, leading to protein denaturation and enzyme inactivation. They also induce lipid peroxidation and generate toxic metabolites that damage cell membranes. In some cases, such as ethylene glycol toxicity, crystal formation occurs within renal tubules, causing obstruction and further injury. These processes ultimately result in acute tubular necrosis^[10].

The ischemia–reperfusion injury (IRI) model is another important experimental approach in which renal blood flow is temporarily interrupted and then restored. During the ischemic phase, reduced blood supply leads to oxygen deprivation, decreased ATP production, and cellular energy failure. Upon reperfusion, the sudden reintroduction of oxygen leads to a burst of reactive oxygen species and activation of inflammatory pathways. This results in endothelial dysfunction, tubular cell injury, apoptosis, and necrosis. This model is particularly relevant in clinical situations such as kidney transplantation and shock^[11].

Surgical models are mainly used to study chronic kidney disease. In the 5/6 nephrectomy model, a significant portion of renal mass is removed, leading to compensatory hyperfiltration in the remaining nephrons. This increases glomerular pressure and eventually causes glomerulosclerosis and fibrosis. In the unilateral ureteral obstruction (UUO) model, blockage of the ureter leads to accumulation of urine, increased intrarenal pressure, and subsequent tubular dilation, inflammation, and interstitial fibrosis. These models are useful for studying long-term structural and functional changes in the kidney^[12].

Disease-induced models simulate systemic conditions that affect renal function. In diabetic nephropathy models, hyperglycemia leads to the formation of advanced glycation end products, oxidative stress, and thickening of the glomerular basement membrane, resulting in proteinuria and glomerular damage. In hypertension-induced models, elevated blood pressure causes vascular damage, reduced renal blood flow, and ischemic injury. Sepsis-induced models involve systemic infection that triggers the release of endotoxins and inflammatory cytokines, leading to microcirculatory dysfunction, tubular injury, and multi-organ failure^[13].

In conclusion, each type of animal model for nephrotoxicity mimics specific mechanisms of kidney injury. These models are essential for understanding the pathophysiology of renal damage, evaluating nephrotoxic effects of drugs, and developing effective therapeutic strategies.

6. Mechanisms of Nephrotoxicity

1. Oxidative Stress

Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defense system. In nephrotoxicity, toxic drugs or chemicals increase ROS levels, which damage cellular components like lipids, proteins, and DNA. This leads to lipid peroxidation, membrane damage, and impaired kidney cell function. Antioxidant enzymes such as superoxide dismutase and catalase become depleted, worsening the injury^[20].

2. Inflammation

Inflammation is a protective response, but in nephrotoxicity it becomes harmful. Toxic agents activate immune cells and trigger the release of pro-inflammatory cytokines such as TNF- α , IL-1, and IL-6. These mediators cause swelling, tissue damage, and leukocyte infiltration in kidney tissues. Chronic inflammation can lead to fibrosis and long-term kidney damage^[21].

3. Apoptosis and Necrosis


Nephrotoxic substances can cause kidney cell death through two main pathways:

- **Apoptosis (programmed cell death):**
A controlled process where cells shrink and die without causing inflammation. It is mediated by caspases and occurs due to DNA damage, oxidative stress, or mitochondrial injury.
- **Necrosis (uncontrolled cell death):**
A severe form of injury where cells swell, rupture, and release contents into surrounding tissue, leading to inflammation and further damage. This is commonly seen in acute kidney injury^[22].

4. Mitochondrial Dysfunction

Mitochondria are responsible for ATP (energy) production. Nephrotoxic agents impair mitochondrial function by disrupting the electron transport chain, leading to **decreased ATP production**. This results in energy depletion, increased ROS generation, and activation of cell death pathways. Mitochondrial damage is a key factor in both apoptosis and necrosis of renal cells^[23].

Mechanisms of Nephrotoxicity



11. Recent Advances in Animal Models

Recent years have seen significant advancements aimed at overcoming the limitations of traditional animal models.

11.1 Genetically Modified Animal Models

Genetically engineered mice have revolutionized nephrology research:

- Knockout models help identify specific gene functions
- Transgenic models mimic human kidney diseases
- CRISPR-Cas9 technology enables precise gene editing

These models allow researchers to study molecular pathways involved in nephrotoxicity and disease progression with high specificity^[24].

11.2 Humanized Animal Models

- Animals implanted with human tissues or genes
- Improve translational relevance
- Useful in drug toxicity and pharmacokinetic studies^[25]

11.3 Kidney Organoids

- Derived from human stem cells
- Mimic nephron structure and function
- Useful for studying:
 - Drug toxicity
 - Disease mechanisms
 - Personalized medicine

Advantages:

- Reduce animal usage
- Human-relevant results

Limitations:

- Lack full vascularization
- Limited long-term stability^[26]

11.4 Kidney-on-a-Chip Technology

- Microfluidic devices simulating kidney function
- Replicate:
 - Fluid flow
 - Filtration
 - Cellular interactions^[27]

Applications:

- Drug screening
- Toxicity prediction
- Disease modeling

These systems improve prediction of human nephrotoxicity compared to traditional models.

11.5 Advanced Imaging Techniques

- MRI and CT imaging in animal models
- Real-time monitoring of kidney function
- Non-invasive assessment

11.6 Biomarker-Based Models

- Use of early biomarkers to detect injury
- Improves sensitivity of nephrotoxicity studies
- Enables early-stage drug screening^[17]

12. Future Perspectives

The future of nephrotoxicity research is rapidly evolving with the aim of developing more accurate, reliable, and human-relevant experimental models. Although traditional animal models have significantly contributed to understanding kidney injury, their limitations in translating results to human conditions have highlighted the need for advanced and innovative approaches^[26,27].

One of the most important future directions is the development of human-relevant models that closely mimic human kidney physiology and pathology. Advanced technologies such as kidney organoids and micro-physiological systems (kidney-on-a-chip) are gaining attention. These systems are derived from human stem cells and are capable of replicating the structural and functional characteristics of nephrons. They allow researchers to study drug-induced toxicity, disease mechanisms, and cellular interactions in a controlled environment. Moreover, these models can reduce the dependency on animal experimentation and provide more clinically relevant data.

Another significant advancement is the use of genetically modified animal models, including transgenic and knockout mice. Modern gene-editing tools such as CRISPR-Cas9 enable precise manipulation of genes involved in kidney injury and repair. These models help in understanding the molecular pathways underlying nephrotoxicity and in identifying novel therapeutic targets. Additionally, humanized animal models, which incorporate human genes or tissues, are expected to improve the predictability of preclinical studies.

The integration of artificial intelligence (AI) and computational modeling represents a promising future approach. AI can analyze large datasets generated from experimental studies and identify patterns associated with nephrotoxicity. Machine learning models can predict drug-induced kidney injury, optimize experimental design, and reduce the number of animals required for testing. This approach supports the concept of precision medicine by enabling individualized risk assessment and treatment strategies^[28].

There is also a growing emphasis on the 3Rs principle (Replacement, Reduction, and Refinement) in animal research. Future studies aim to replace animal models with alternative methods wherever possible, reduce the number of animals used, and refine experimental techniques to minimize suffering. The adoption of in vitro models, organoids, and computer-based simulations aligns with these ethical considerations^[29].

Another important area is the development of multi-organ interaction models, which simulate the interactions between the kidney and other organs such as the liver, heart, and immune system. Since nephrotoxicity often occurs as part of systemic toxicity, these integrated models provide a more comprehensive understanding of disease mechanisms and drug effects.

Furthermore, future research is focusing on the identification of novel and sensitive biomarkers for early detection of kidney injury. Biomarkers such as KIM-1, NGAL, and cystatin C are being extensively studied to improve diagnostic accuracy and to monitor disease progression and treatment response^[17].

Despite these advancements, several challenges remain, including the high cost of advanced technologies, technical complexity, and the need for standardization of experimental protocols. However, continuous innovation and interdisciplinary collaboration are expected to overcome these limitations.

In conclusion, the future of nephrotoxicity research lies in the integration of advanced experimental models, genetic technologies, computational tools, and ethical practices. These developments will enhance our understanding of kidney diseases, improve drug safety evaluation, and ultimately lead to better clinical outcomes

13. Conclusion

Animal models play a pivotal and indispensable role in the study of nephrotoxicity and kidney injury. They provide a structured and controlled platform to investigate the complex mechanisms underlying renal damage, including oxidative stress, inflammation, apoptosis, and hemodynamic alterations. Through these models, researchers have been able to understand how various nephrotoxic agents such as drugs, chemicals, and environmental toxins affect different components of the kidney, particularly the glomeruli and renal tubules^[1,3].

Different types of animal models, including drug-induced, chemical-induced, ischemia–reperfusion, surgical, and disease-induced models, each contribute unique insights into specific aspects of kidney injury. These models help in simulating both acute and chronic forms of renal damage, thereby enabling the study of disease initiation, progression, and long-term complications^[24,25,27]. Moreover, the use of commonly employed laboratory animals such as rats and mice has facilitated reproducibility and standardization in experimental nephrology research.

Animal models are also essential for preclinical drug evaluation, allowing researchers to assess the nephrotoxic potential of new therapeutic agents before human trials. They aid in determining safe dosage levels, identifying adverse effects, and evaluating the efficacy of nephroprotective strategies. In addition, these models have contributed significantly to the identification of early biomarkers for kidney injury, which are crucial for timely diagnosis and intervention.

Despite their numerous advantages, traditional animal models have certain limitations, particularly in translating experimental findings to human clinical conditions due to interspecies differences. This has led to the development of advanced approaches such as genetically modified animals, humanized models, kidney organoids, and micro physiological systems, which aim to improve the relevance and predictive accuracy of nephrotoxicity studies.

Looking forward, the integration of innovative technologies such as artificial intelligence, advanced imaging, and multi-organ models is expected to enhance the understanding of kidney diseases and improve drug safety assessment. At the same time, ethical considerations, including the adoption of the 3Rs principle (Replacement, Reduction, and Refinement), are becoming increasingly important in guiding research practices.

In conclusion, while animal models remain a cornerstone of nephrotoxicity research, future advancements will focus on developing more precise, ethical, and human-relevant systems. These efforts will ultimately contribute to better prevention, diagnosis, and treatment of kidney diseases, thereby improving patient outcomes and advancing the field of clinical pharmacology and toxicology.

REFERENCES

1. Liang J, Liu Y. Animal models of kidney disease: challenges and perspectives. *Kidney360*. 2023;4(10):1479–1493.
2. Bao YW, Yuan Y, Chen JH, Lin WQ. Kidney disease models. *Zool Res*. 2018;39(2):72–86.
3. Miao J, Zhu H, Wang J, Chen J, Han F, Lin W. Experimental models for kidney disease. *Zool Res*. 2024;45(5):1161–1174.
4. Foreman KJ, et al. Global burden of disease. *Lancet*. 2018;392:2052–2090.
5. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function. *Clin Chim Acta*. 2015;438:350–357.
6. KDIGO Clinical Practice Guidelines for AKI. *Kidney Int Suppl*. 2012;2:1–138.
7. Pabla N, Dong Z. Cisplatin nephrotoxicity. *Kidney Int*. 2008;73:994–1007.
8. Mehta RL, et al. Acute kidney injury. *Lancet*. 2015;385:2616–2628.
9. Vanmassenhove J, et al. Nephrotoxicity mechanisms. *Crit Care*. 2013;17:R123.
10. Doi K, et al. Ischemia reperfusion injury. *Kidney Int*. 2008;74:1017–1025.

11. Ortiz A, et al. Translational models in nephrology. *Eur J Pharmacol.* 2015;759:205–220.
12. Pérez-López L, et al. Diabetic nephropathy models. *Adv Exp Med Biol.* 2021;1307:521–551.
13. Ronco C, et al. Pathophysiology of AKI. *Lancet.* 2015;385:2616–2628.
14. Sharp CN, Siskind LJ. Oxidative stress in kidney injury. 2017.
15. Schiff H, Lang SM. Inflammation in AKI. *Nephrol Dial Transplant.* 2012.
16. Linkermann A, et al. Regulated cell death. *Nat Rev Nephrol.* 2014.
17. Zorov DB, et al. Mitochondrial ROS. *J Exp Med.* 2014.
18. Nigam SK. Drug transporters and kidney. *Nat Rev Drug Discov.* 2015.
19. Bonventre JV. Mechanisms of AKI. *J Clin Invest.* 2011.
20. Vaidya VS, et al. Biomarkers of AKI. *Kidney Int.* 2008.
21. Homan KA, et al. Kidney organoids. *Nat Methods.* 2019.
22. Jang KJ, Suh KY. Kidney-on-chip. *Lab Chip.* 2010.
23. Low JH, et al. Organoid kidney models. *Nat Rev Nephrol.* 2021.
24. Marx U, et al. Microphysiological systems. *ALTEX.* 2020.
25. Ingber DE. Human organ chips. *Cell.* 2022.
26. Topol EJ. AI in medicine. *Nat Med.* 2019.
27. He J, et al. Machine learning in healthcare. *Nat Med.* 2019.
28. OECD Guidelines for toxicity testing. 2021.
29. WHO Global Kidney Report. 2019.
30. US FDA Drug Safety Guidelines. 2021

